{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:06:35Z","timestamp":1793973995170,"version":"4.8.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016359"],"award-info":[{"award-number":["P30 CA016359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.blre.2020.100706","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T21:32:54Z","timestamp":1590096774000},"page":"100706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map"],"prefix":"10.1016","volume":"42","author":[{"given":"Rory M.","family":"Shallis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Davidoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100706_bb0005","series-title":"WHO classification of Tumours of Haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.blre.2020.100706_bb0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100706_bb0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2020.100706_bb0025","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic risk assessment in myeloproliferative neoplasms","volume":"92","author":"Tefferi","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2020.100706_bb0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3324\/haematol.2013.101279","article-title":"Mutational spectrum defines primary and secondary myelofibrosis","volume":"99","author":"Mills","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100706_bb0040","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","article-title":"Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome","volume":"92","author":"Yogarajah","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2020.100706_bb0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2020.100706_bb0050","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0060","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2020.100706_bb0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science."},{"key":"10.1016\/j.blre.2020.100706_bb0070","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100706_bb0075","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0080","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100706_bb0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2020.100706_bb0090","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0095","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0100","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.blre.2020.100706_bb0110","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100706_bb0115","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100706_bb0120","series-title":"International Classification of Diseases for Oncology","author":"Fritz","year":"2000"},{"key":"10.1016\/j.blre.2020.100706_bb0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0130","series-title":"About the SEER registries","author":"Noone","year":"2018"},{"key":"10.1016\/j.blre.2020.100706_bb0135","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2016\/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019. https:\/\/seer.cancer.gov\/csr\/1975_2016\/."},{"key":"10.1016\/j.blre.2020.100706_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0150","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1182\/blood-2018-99-110619","article-title":"Prevalence of <em>JAK2<\/em> V617F in individuals that meet World Health Organization Erythrocytosis criteria for polycythemia Vera","volume":"132","author":"Piris-Villaespesa","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0155","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/PAS.0000000000000749","article-title":"The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship","volume":"40","author":"Duggan","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2020.100706_bb0160","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"Hoglund","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0165","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ejh.12788","article-title":"Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway","volume":"98","author":"Roaldsnes","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0180","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1002\/ajh.25407","article-title":"Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014","volume":"94","author":"Baade","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0185","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00277-016-2902-9","article-title":"Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013","volume":"96","author":"Byun","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-018-0124-7","article-title":"The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia","volume":"7","author":"Yap","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ajh.21333","article-title":"Jakking up tumor registry reporting of the myeloproliferative neoplasms","volume":"84","author":"Selinger","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0200","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100706_bb0205","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12185-015-1893-y","article-title":"Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia","volume":"103","author":"Mendizabal","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0210","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/cam4.2201","article-title":"Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute - Mexico, from 2000 to 2016","volume":"8","author":"Ylescas-Soria","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2020.100706_bb0215","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2020.100706_bb0225","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2020.100706_bb0230","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0235","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2020.100706_bb0245","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.25351","article-title":"20+ years and alive with primary myelofibrosis: phenotypic signature of very long-lived patients","volume":"94","author":"Penna","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0250","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090299","article-title":"Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN)","volume":"9","author":"Price","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2020.100706_bb0260","series-title":"Relative survival","author":"Noone","year":"2018"},{"key":"10.1016\/j.blre.2020.100706_bb0265","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100706_bb0270","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0275","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0280","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus Imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0285","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2020.100706_bb0290","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0295","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1182\/blood.V128.22.2380.2380","article-title":"100 years of chronic myeloid leukemia prevalence in France","volume":"128","author":"Delord","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0300","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2020.100706_bb0305","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A long-term retrospective study of young women with essential thrombocythemia","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2020.100706_bb0310","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","article-title":"Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study","volume":"98","author":"Maynadie","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100706_bb0315","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0320","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0325","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0330","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0335","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0340","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0345","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1200\/jco.2008.26.15_suppl.7088","article-title":"Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib","volume":"26","author":"Corm","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0350","series-title":"Leukemia - Chronic Myeloid Leukemia (CML)","author":"Cancer Stat Facts","year":"2019"},{"key":"10.1016\/j.blre.2020.100706_bb0355","series-title":"2010 - Census Bureau","author":"Age and Sex Composition","year":"2011"},{"key":"10.1016\/j.blre.2020.100706_bb0360","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2020.100706_bb0365","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia","volume":"83","author":"Ma","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0370","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0375","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0380","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0385","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100706_bb0390","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100706_bb0395","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0400","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100706_bb0405","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0410","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100706_bb0415","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2020.100706_bb0420","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ijlh.12380","article-title":"JAK2 46\/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients","volume":"37","author":"Macedo","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0425","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-013-1295-y","article-title":"JAK2 46\/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients","volume":"97","author":"Tanaka","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0430","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2013.21","article-title":"JAK2V617F allele burden, JAK2 46\/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0435","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.14713","article-title":"Advances in understanding the pathogenesis of familial myeloproliferative neoplasms","volume":"178","author":"Rumi","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0440","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.leukres.2011.09.029","article-title":"Influence of JAK2 46\/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms","volume":"36","author":"Alvarez-Larran","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100706_bb0445","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0450","first-page":"27","article-title":"The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms","volume":"6","author":"Bahar","year":"2016","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.blre.2020.100706_bb0455","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijbiomac.2018.05.120","article-title":"Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms","volume":"116","author":"Wu","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.blre.2020.100706_bb0460","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood-2012-05-430926","article-title":"Impact of isolated germline JAK2V617I mutation on human hematopoiesis","volume":"121","author":"Mead","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0465","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0470","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.23614","article-title":"A novel germline JAK2 mutation in familial myeloproliferative neoplasms","volume":"89","author":"Rumi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0475","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41375-018-0356-x","article-title":"The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters","volume":"33","author":"Defour","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0480","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0485","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajh.20105","article-title":"A case of familial thrombocytosis: possible role of altered thrombopoietin production","volume":"76","author":"Fujiwara","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0490","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V94.4.1480","article-title":"A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA","volume":"94","author":"Ghilardi","year":"1999","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0495","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2141.1999.01710.x","article-title":"Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene","volume":"107","author":"Ghilardi","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0500","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3324\/haematol.11801","article-title":"A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family","volume":"93","author":"Liu","year":"2008","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100706_bb0505","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00277-012-1453-y","article-title":"Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects","volume":"91","author":"Stockklausner","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0510","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1182\/blood.V128.22.5494.5494","article-title":"Germline Calr mutation and thrombocytosis presenting with concomitant BCR-ABL1+ CML","volume":"128","author":"Baughn","year":"2016","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2020.100706_bb0515","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jclinpath-2016-203940","article-title":"Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms","volume":"69","author":"Szuber","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2020.100706_bb0520","doi-asserted-by":"crossref","first-page":"76204","DOI":"10.18632\/oncotarget.19211","article-title":"Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population","volume":"8","author":"Chiang","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2020.100706_bb0525","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ajh.23842","article-title":"Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms","volume":"89","author":"Jager","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0530","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/leu.2014.48","article-title":"The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms","volume":"28","author":"Oddsson","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0535","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2020.100706_bb0540","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2020.100706_bb0545","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0002-9343(52)90285-4","article-title":"Incidence of leukemia in survivors of the atomic bomb in Hiroshima and Nagasaki, Japan","volume":"13","author":"Folley","year":"1952","journal-title":"Am J Med"},{"issue":"Suppl","key":"10.1016\/j.blre.2020.100706_bb0550","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1269\/jrr.32.SUPPLEMENT_162","article-title":"Atomic bomb and leukemia","volume":"32","author":"Ichimaru","year":"1991","journal-title":"J Radiat Res"},{"key":"10.1016\/j.blre.2020.100706_bb0555","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1667\/RR2892.1","article-title":"The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001","volume":"179","author":"Hsu","year":"2013","journal-title":"Radiat Res"},{"key":"10.1016\/j.blre.2020.100706_bb0560","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","article-title":"The epidemiology of autoimmune diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2020.100706_bb0565","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100706_bb0570","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2020.100706_bb0575","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.beha.2019.02.002","article-title":"Myeloid disorders after autoimmune disease","volume":"32","author":"Boddu","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0580","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ejh.13092","article-title":"The genetic and molecular pathogenesis of myelodysplastic syndromes","volume":"101","author":"Shallis","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0585","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ijc.28492","article-title":"Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women\u2019s Health Study cohort","volume":"134","author":"Leal","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2020.100706_bb0590","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1158\/1055-9965.EPI-11-0411","article-title":"Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia","volume":"20","author":"Ross","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.blre.2020.100706_bb0595","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.canep.2015.09.003","article-title":"Epidemiology of adult acute myeloid leukemia: impact of exposures on clinical phenotypes and outcomes after therapy","volume":"39","author":"Finn","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.blre.2020.100706_bb0600","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"Reilly","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.blre.2020.100706_bb0605","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1055-9965.EPI-09-0028","article-title":"Obesity, weight gain, and risk of chronic myeloid leukemia","volume":"18","author":"Strom","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.blre.2020.100706_bb0610","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1182\/blood-2012-09-458463","article-title":"Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy","volume":"120","author":"Aduwa","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0615","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1158\/1055-9965.EPI-13-0093","article-title":"Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP Diet and Health Study","volume":"22","author":"Kabat","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.blre.2020.100706_bb0620","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ejh.12684","article-title":"Smoking and Philadelphia-negative chronic myeloproliferative neoplasms","volume":"97","author":"Lindholm Sorensen","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0625","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.canep.2013.03.012","article-title":"Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation","volume":"37","author":"Musselman","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.blre.2020.100706_bb0630","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1002\/cam4.1815","article-title":"Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2020.100706_bb0635","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/10245332.2016.1232011","article-title":"Relationship between cigarette smoking and risk of chronic myeloid leukaemia: a meta-analysis of epidemiological studies","volume":"22","author":"Qin","year":"2017","journal-title":"Hematology."},{"key":"10.1016\/j.blre.2020.100706_bb0640","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12693","article-title":"Determining the role of smoking in myeloproliferative neoplasms: is it a matter of picking the right control group?","volume":"97","author":"Pulte","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0645","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2020.100706_bb0650","first-page":"587","article-title":"Testing Sokal\u2019s and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia","volume":"111","author":"Bonifazi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0655","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2020.100706_bb0660","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","article-title":"Outcomes and predictors of survival in blast phase myeloproliferative neoplasms","volume":"70","author":"Lancman","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100706_bb0665","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clml.2015.09.007","article-title":"Prognostic factors, response to treatment, and survival in patients with chronic myeloid leukemia in blast phase: a single-institution survey","volume":"15","author":"Perez-Jacobo","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2020.100706_bb0670","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0675","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0680","doi-asserted-by":"crossref","first-page":"E661","DOI":"10.1002\/ajh.24913","article-title":"The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials","volume":"92","author":"Molica","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0685","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0690","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/bloodadvances.2018018614","article-title":"Imatinib is still recommended for frontline therapy for CML","volume":"2","author":"Hantel","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100706_bb0695","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/14656566.2019.1599357","article-title":"What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?","volume":"20","author":"Shallis","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2020.100706_bb0700","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/cncr.30636","article-title":"Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death","volume":"123","author":"Lauseker","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2020.100706_bb0705","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0710","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3109\/0284186X.2012.707784","article-title":"Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US","volume":"52","author":"Mandal","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.blre.2020.100706_bb0715","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2403756","article-title":"Gender aspects in chronic myeloid leukemia: long-term results from randomized studies","volume":"19","author":"Berger","year":"2005","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100706_bb0720","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004266","article-title":"Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort","volume":"4","author":"Smith","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.blre.2020.100706_bb0725","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100706_bb0730","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0735","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100706_bb0740","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","article-title":"The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera","volume":"2","author":"Podoltsev","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100706_bb0745","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2018.7095","article-title":"Impact of hydroxyurea on survival and risk of thrombosis among older patients with essential Thrombocythemia","volume":"17","author":"Podoltsev","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2020.100706_bb0750","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.12990","article-title":"WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes","volume":"166","author":"Alvarez-Larran","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100706_bb0755","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/modpathol.2013.196","article-title":"Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"27","author":"Gianelli","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2020.100706_bb0760","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ajh.23554","article-title":"World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience","volume":"88","author":"Madelung","year":"2013","journal-title":"Am J Hematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:55Z","timestamp":1759436635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":152,"alternative-id":["S0268960X20300564"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100706","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100706"}}